GleamWall
中文EN

BCAB BioAtla, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1826892 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY63.6%
TTM EPS YoY177.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-277.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets4,031.1%
Debt / equity—
Current ratio0.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio-105.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$43.57M$63.09M
SG&A expense$17.73M$21.85M
Operating income-$59.30M-$73.94M
Income tax$0$0
Net income-$59.61M-$69.78M
EBITDA-$58.93M-$73.02M
EPS (basic)-1.01-1.44
EPS (diluted)-1.01-1.44
Weighted avg. shares (diluted)58.83M48.57M
Balance sheet
Cash & equivalents$7.12M$49.05M
Receivables$0—
Current assets$8.01M$51.23M
PP&E, net$120,000$678,000
Total assets$13.83M$52.42M
Current liabilities$21.92M$14.54M
Total liabilities$50.02M$38.16M
Shareholders' equity-$36.19M$14.27M
Shares outstanding1.27M58.10M
Cash flow statement
Operating cash flow-$48.20M-$71.94M
Investing cash flow—$0
Financing cash flow$6.28M$9.51M
Depreciation & amortization$373,000$925,000
Stock-based compensation$5.43M$8.92M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.